BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 10750574)

  • 1. The effect of alendronate on bone mass after distal forearm fracture.
    van der Poest Clement E; Patka P; Vandormael K; Haarman H; Lips P
    J Bone Miner Res; 2000 Mar; 15(3):586-93. PubMed ID: 10750574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clodronate increases mineralization of callus after Colles' fracture: a randomized, double-blind, placebo-controlled, prospective trial in 32 patients.
    Adolphson P; Abbaszadegan H; Bodén H; Salemyr M; Henriques T
    Acta Orthop Scand; 2000 Apr; 71(2):195-200. PubMed ID: 10852328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
    Khan AA; Bilezikian JP; Kung AW; Ahmed MM; Dubois SJ; Ho AY; Schussheim D; Rubin MR; Shaikh AM; Silverberg SJ; Standish TI; Syed Z; Syed ZA
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forearm bone mineral densitometry cannot be used to monitor response to alendronate therapy in postmenopausal women.
    Bouxsein ML; Parker RA; Greenspan SL
    Osteoporos Int; 1999; 10(6):505-9. PubMed ID: 10663352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone loss from the hand in women following distal forearm fracture.
    Ingle BM; Eastell R
    Osteoporos Int; 2001; 12(7):610-5. PubMed ID: 11527061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.
    Body JJ; Gaich GA; Scheele WH; Kulkarni PM; Miller PD; Peretz A; Dore RK; Correa-Rotter R; Papaioannou A; Cumming DC; Hodsman AB
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4528-35. PubMed ID: 12364430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of bone mineral density with deformity of the distal radius in low-energy Colles' fractures in Japanese women above 50 years of age.
    Sakai A; Oshige T; Zenke Y; Suzuki M; Yamanaka Y; Nakamura T
    J Hand Surg Am; 2008; 33(6):820-6. PubMed ID: 18656750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colles' fracture of the wrist as an indicator of underlying osteoporosis in postmenopausal women: a prospective study of bone mineral density and bone turnover rate.
    Earnshaw SA; Cawte SA; Worley A; Hosking DJ
    Osteoporos Int; 1998; 8(1):53-60. PubMed ID: 9692078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alendronate in the prevention of bone loss after a fracture of the lower leg.
    van der Poest Clement E; van Engeland M; Adèr H; Roos JC; Patka P; Lips P
    J Bone Miner Res; 2002 Dec; 17(12):2247-55. PubMed ID: 12469919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in bone mass and bone turnover following distal forearm fracture.
    Ingle BM; Hay SM; Bottjer HM; Eastell R
    Osteoporos Int; 1999; 10(5):399-407. PubMed ID: 10591838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial.
    Watts NB; Dore RK; Baim S; Mitlak B; Hattersley G; Wang Y; Rozental TD; LeBoff MS
    Osteoporos Int; 2021 Jan; 32(1):55-61. PubMed ID: 32935170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alendronate increases bone density and bone strength at the distal radius in postmenopausal women.
    Schneider PF; Fischer M; Allolio B; Felsenberg D; Schröder U; Semler J; Ittner JR
    J Bone Miner Res; 1999 Aug; 14(8):1387-93. PubMed ID: 10457271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    Yonsei Med J; 2004 Aug; 45(4):676-82. PubMed ID: 15344210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colles' fracture and bone density of the ultradistal radius.
    Eastell R; Riggs BL; Wahner HW; O'Fallon WM; Amadio PC; Melton LJ
    J Bone Miner Res; 1989 Aug; 4(4):607-13. PubMed ID: 2816507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
    Ensrud KE; Barrett-Connor EL; Schwartz A; Santora AC; Bauer DC; Suryawanshi S; Feldstein A; Haskell WL; Hochberg MC; Torner JC; Lombardi A; Black DM;
    J Bone Miner Res; 2004 Aug; 19(8):1259-69. PubMed ID: 15231012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group.
    Pols HA; Felsenberg D; Hanley DA; Stepán J; Muñoz-Torres M; Wilkin TJ; Qin-sheng G; Galich AM; Vandormael K; Yates AJ; Stych B
    Osteoporos Int; 1999; 9(5):461-8. PubMed ID: 10550467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
    Rizzoli R; Greenspan SL; Bone G; Schnitzer TJ; Watts NB; Adami S; Foldes AJ; Roux C; Levine MA; Uebelhart B; Santora AC; Kaur A; Peverly CA; Orloff JJ;
    J Bone Miner Res; 2002 Nov; 17(11):1988-96. PubMed ID: 12412806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.